echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > METTL3 inhibitor sTC-15 treats acute myeloid leukemia.

    METTL3 inhibitor sTC-15 treats acute myeloid leukemia.

    • Last Update: 2020-10-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Acute myeloid leukemia (AML) is the most common type of leukemia in adults, but it can affect people of all ages.
    , AML is caused by chemotherapy or radiotherapy used to treat another cancer.
    in AML, immature leukemia cells quickly gather in the bone marrow, destroying and replacing normal hematocytes.
    leukemia cells are released into the bloodstream and transported to other organs, where they continue to grow and divide.
    , a spin-off company at the University of Cambridge, announced that its state-of-the-art METTL3 inhibitors are in clinical trials.
    STC-15 is an oral small molecule METTL3 inhibitor used to treat acute myeloid leukemia and other solid and blood cancers.
    company uses its drug discovery capabilities, as well as analytical techniques developed specifically for RNA oscic genetics, to produce highly effective selective small molecule inhibitors for METTL3 and other RNA modifier enzymes.
    The sTC-15 is an efficient and selective METTL3 inhibitor, and patients with acute myeloid leukemia will be included in the initial clinical trials," said Keith Blundy, CEO of STORM Therapeutics.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.